GI Update and Coding from the Endoscopy Report Basic and Advanced

Poor communication contributes to 80% of medical errors (the 3rd leading cause of death), ⅓ of all malpractice suits, poor outcomes and redundant costs. Unfortunately, these miscommunications are abundant because our care teams are stuck in communication silos. That's why we need to unify ALL systems of care for ALL time sensitive emergencies with regional communication networks that connect ALL members of the care team -- from prehospital providers to interfacility teams to those at other hospitals outside of our own.

Learn more on burn injury, prevention and the immediate care needed for patients with burn injuries. In the United States, approximately 486,000 people seek medical treatment for burns each year. Many people may not recognize their risk of burn injury. It will cover the classification system used for burn injuries describe the local and systemic effects of a major burn injury, discuss the potential fluid and electrolyte alterations of the emergent/resuscitative and acute phases of burn management, describe care of the patient with burn injuries, and identify the appropriate patient referral to a burn center.

Small cell lung cancer (SCLC) is aggressive and often difficult to treat, but many patients may have new hope. On August 17, 2018, the FDA approved the first immunotherapy the checkpoint inhibitor nivolumab (Opdivo, Bristol-Myers Squibb for patients with small cell lung cancer. Since this approval, there has been renewed focus on how to make different immunotherapies work for a disease which typicallly comprises 10-15% of all lung cancer cases. In this webinar for patients and caregivers, Matthew Hellmann, M.D., of Memorial Sloan Kettering Cancer Center discusses the new FDA approval, clinical trials, and potential treatments for patients with small cell lung cancer.

Do you need reliable pharmacokinetic data (PK) to evaluate human immunoglobulin or albumin-based therapeutic drug candidates? The humanized FcRn (Hu-FcRn) mouse model enables you to obtain clinically-relevant PK data related to drug half-life. This critically important PK data helps optimize the design of preclinical efficacy studies and to de-risk lead selection.